M, E., SM, W., AY, C., IW, B., G, B., C, H., . . . SM, P. (2026). Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany. The European journal of health economics : HEPAC : health economics in prevention and care. https://doi.org/10.1007/s10198-025-01890-4
Chicago Style (17th ed.) CitationM, Engelhard, et al. "Healthcare Resource Utilization and Costs of Letermovir for Cytomegalovirus-prophylaxis After Allogeneic Hematopoietic Cell Transplantation in a Real-world, Multi-centre Study in Germany." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care 2026. https://doi.org/10.1007/s10198-025-01890-4.
MLA (9th ed.) CitationM, Engelhard, et al. "Healthcare Resource Utilization and Costs of Letermovir for Cytomegalovirus-prophylaxis After Allogeneic Hematopoietic Cell Transplantation in a Real-world, Multi-centre Study in Germany." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 2026, https://doi.org/10.1007/s10198-025-01890-4.
